Company Filing History:
2 out of 1,743 
1 out of 290 
1 out of 4,872 
Years Active: 2012-2023
Title: The Innovative Contributions of Christophe Bosc
Introduction
Christophe Bosc is a notable inventor based in Grenoble, France. He has made significant contributions to the field of pharmaceutical sciences, particularly in the treatment of diseases associated with tubulin carboxypeptidases. With a total of 2 patents, his work has implications for neurological and cardiovascular disorders.
Latest Patents
Bosc's latest patents include methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases. His research has identified the major brain tubulin carboxypeptidase (TCP) as a complex of vasohibin-1 (VASH1) with the Small Vasohibin-Binding Protein (SVBP). This discovery highlights the enzymatic activity of the vasohibin/SVBP complex, which plays a crucial role in microtubule dynamics. Furthermore, his work demonstrates that the knockdown of vasohibins or SVBP in cultured neurons leads to a significant reduction in tyrosinated α-tubulin levels, resulting in severe differentiation defects and disrupted neuronal migration in the developing mouse neocortex. His second patent involves transgenic or recombinant non-human mammals, which are utilized in screening medicines for schizophrenia and schizo-affective disorders.
Career Highlights
Throughout his career, Christophe Bosc has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and Les Laboratoires Servier. His research has not only advanced scientific understanding but also paved the way for potential therapeutic interventions.
Collaborations
Bosc has collaborated with notable colleagues, including Annie Andrieux and Marie-José Moutin. These partnerships have contributed to the depth and breadth of his research endeavors.
Conclusion
Christophe Bosc's innovative work in the field of pharmaceutical sciences has led to significant advancements in understanding and treating diseases associated with tubulin carboxypeptidases. His contributions continue to influence the development of new therapeutic strategies.